Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has shown resilience with a 15% increase over the past year and expectations for earnings to grow by 16% annually in the coming years. In this context of fluctuating short-term performance but promising long-term growth prospects, identifying high growth tech stocks that can capitalize on these trends becomes essential for investors seeking potential opportunities.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Marker Therapeutics | 61.33% | 65.71% | ★★★★★★ |
| Palantir Technologies | 27.02% | 31.25% | ★★★★★★ |
| Sandisk | 30.23% | 46.19% | ★★★★★★ |
| 22.20% | 27.96% | ★★★★★★ | |
| Gorilla Technology Group | 54.35% | 95.02% | ★★★★★☆ |
| Tenaya Therapeutics | 58.52% | 60.10% | ★★★★★☆ |
| Zscaler | 15.93% | 48.88% | ★★★★★☆ |
| Duos Technologies Group | 53.76% | 155.11% | ★★★★★☆ |
| Procore Technologies | 12.08% | 99.98% | ★★★★★☆ |
| KVH Industries | 25.44% | 135.75% | ★★★★★☆ |
Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
BioMarin Pharmaceutical (BMRN)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for life-threatening rare diseases and medical conditions globally, with a market cap of approximately $10.69 billion.
Operations: BioMarin Pharmaceutical generates revenue primarily from the development and commercialization of innovative therapies, amounting to $3.22 billion. The company operates across various international markets, focusing on life-threatening rare diseases and medical conditions.
BioMarin Pharmaceutical, despite a challenging year with a 18.3% decline in earnings, is poised for recovery with expected annual earnings growth of 27.4%, outpacing the US market forecast of 15.6%. The firm's commitment to innovation is evident from its significant R&D investment, aligning with a revenue increase to $3.22 billion from $2.85 billion previously. Recent FDA approvals and positive trial outcomes for VOXZOGO suggest resilience and potential growth in its specialized therapeutic segments, although recent discontinuations in other trials underscore the risks inherent in biotech development.
- Take a closer look at BioMarin Pharmaceutical's potential here in our health report.
Gain insights into BioMarin Pharmaceutical's past trends and performance with our Past report.
Kiniksa Pharmaceuticals International (KNSA)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing medical therapies across the United States, the United Kingdom, and internationally, with a market cap of approximately $3.51 billion.
Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, amounting to $677.56 million. The company operates within the biopharmaceutical sector, focusing on medical therapies across various international markets.
Kiniksa Pharmaceuticals International has demonstrated a notable turnaround, transitioning from a net loss to reporting a net income of $59.01 million in the recent fiscal year, up from a previous loss of $43.19 million. This financial recovery is underscored by an impressive annual revenue jump to $677.56 million, marking an increase from $423.24 million, reflecting robust growth and operational efficiency improvements under new executive leadership with strategic focuses including AI initiatives. The firm's R&D commitment remains strong, vital for sustaining innovation and competitive edge in the biotech landscape.
Klaviyo (KVYO)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Klaviyo, Inc. offers a cloud-based software-as-a-service platform across various regions including the United States, Asia-Pacific, and Europe, with a market cap of $5.53 billion.
Operations: Klaviyo generates revenue primarily from its Internet Software segment, totaling $1.23 billion.
Klaviyo, amidst a transformative phase in tech, has shown robust financial and innovative prowess. With an annual revenue growth of 16.2% and earnings poised to surge by 81.7% annually, the company's strategic focus on R&D is evident from its recent launch of Composer and expansion into AI-driven marketing solutions. These initiatives are supported by a substantial $500 million share repurchase program, underscoring confidence in its trajectory. Moreover, Klaviyo's deepened integration with Shopify highlights its commitment to enhancing global brand services through advanced CRM capabilities, setting a strong foundation for sustained growth in the dynamic digital marketing sector.
- Click to explore a detailed breakdown of our findings in Klaviyo's health report.
Review our historical performance report to gain insights into Klaviyo's's past performance.
Next Steps
- Explore the 73 names from our US High Growth Tech and AI Stocks screener here.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com